Literature DB >> 8770496

Regulation of early complement components C3 and C4 in the synovium.

T Collins1, J A Winkelstein, K E Sullivan.   

Abstract

To determine the cytokine inducibility of early complement component (C3 and C4) expression in the synovium, explant tissue was maintained in culture for 7 days. C3 and C4 production was measured by specific enzyme-linked immunosorbent assay, and RNA was evaluated by semiquantitative PCR. The effects of leukemia inhibitory factor (LIF), gamma interferon (IFN-gamma), IFN-alpha, and estrogen on C3 and C4 expression were evaluated. C3 levels were unaffected by 7 days of LIF, IFN-gamma, or IFN-alpha treatment. In contrast, C4 levels were significantly induced in synovial samples treated for 7 days with either IFN-gamma or IFN-alpha. LIF had no effect on C4 levels in this system. Estrogen was found to down-modulate the induction of expression due to IFN-gamma. These data provide evidence for cytokine regulation of C4 expression in the synovium and for estrogen modulation of those effects.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8770496      PMCID: PMC170239          DOI: 10.1128/cdli.3.1.5-9.1996

Source DB:  PubMed          Journal:  Clin Diagn Lab Immunol        ISSN: 1071-412X


  43 in total

1.  Biosynthesis and secretion of complement component (C3) by activated human polymorphonuclear leukocytes.

Authors:  M Botto; D Lissandrini; C Sorio; M J Walport
Journal:  J Immunol       Date:  1992-08-15       Impact factor: 5.422

2.  Rheumatoid arthritis-like disease after alpha-interferon therapy.

Authors:  P Chazerain; O Meyer; M F Kahn
Journal:  Ann Intern Med       Date:  1992-03-01       Impact factor: 25.391

3.  Articular manifestations of systemic lupus erythematosus.

Authors:  R Labowitz; H R Schumacher
Journal:  Ann Intern Med       Date:  1971-06       Impact factor: 25.391

4.  Leukemia inhibitory factor is expressed in cartilage and synovium and can contribute to the pathogenesis of arthritis.

Authors:  M Lotz; T Moats; P M Villiger
Journal:  J Clin Invest       Date:  1992-09       Impact factor: 14.808

5.  Effect of interferon-gamma on complement gene expression in different cell types.

Authors:  D F Lappin; D Guc; A Hill; T McShane; K Whaley
Journal:  Biochem J       Date:  1992-01-15       Impact factor: 3.857

6.  Induction of leukemia inhibitory factor in human synovial fibroblasts by IL-1 and tumor necrosis factor-alpha.

Authors:  J A Hamilton; P M Waring; E L Filonzi
Journal:  J Immunol       Date:  1993-02-15       Impact factor: 5.422

7.  Restricted cytokine expression in rheumatoid arthritis.

Authors:  E Chen; E C Keystone; E N Fish
Journal:  Arthritis Rheum       Date:  1993-07

8.  Detection of cytokines at the cartilage/pannus junction in patients with rheumatoid arthritis: implications for the role of cytokines in cartilage destruction and repair.

Authors:  C Q Chu; M Field; S Allard; E Abney; M Feldmann; R N Maini
Journal:  Br J Rheumatol       Date:  1992-10

9.  Leukemia inhibitory factor levels are elevated in septic shock and various inflammatory body fluids.

Authors:  P Waring; K Wycherley; D Cary; N Nicola; D Metcalf
Journal:  J Clin Invest       Date:  1992-11       Impact factor: 14.808

10.  Production of leukemia inhibitory factor by human articular chondrocytes and cartilage in response to interleukin-1 and tumor necrosis factor alpha.

Authors:  I K Campbell; P Waring; U Novak; J A Hamilton
Journal:  Arthritis Rheum       Date:  1993-06
View more
  2 in total

1.  Transcriptional control of complement activation in an exercise model of chronic fatigue syndrome.

Authors:  Bristol Sorensen; James F Jones; Suzanne D Vernon; Mangalathu S Rajeevan
Journal:  Mol Med       Date:  2008-11-10       Impact factor: 6.354

2.  High abundance synovial fluid proteome: distinct profiles in health and osteoarthritis.

Authors:  Reuben Gobezie; Alvin Kho; Bryan Krastins; David A Sarracino; Thomas S Thornhill; Michael Chase; Peter J Millett; David M Lee
Journal:  Arthritis Res Ther       Date:  2007       Impact factor: 5.156

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.